MedPath

Randomized, Controlled, Double-Blind Study of Itraconazole Oral Solution Versus Fluconazole Tablets for the Treatment of Esophageal Candidiasis.

Not Applicable
Completed
Conditions
Candidiasis, Esophageal
HIV Infections
Registration Number
NCT00002132
Lead Sponsor
Janssen Pharmaceuticals
Brief Summary

To evaluate the safety and efficacy of itraconazole oral solution versus fluconazole tablets for the treatment of esophageal candidiasis in immunocompromised patients.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (18)

Dr Eskild A Petersen

🇺🇸

Tucson, Arizona, United States

Los Angeles County - USC Med Ctr

🇺🇸

Los Angeles, California, United States

UCSD Med Ctr

🇺🇸

San Diego, California, United States

George Washington Univ Med Ctr

🇺🇸

Washington, District of Columbia, United States

Emory Univ School of Medicine

🇺🇸

Atlanta, Georgia, United States

Rush Presbyterian - Saint Luke's Med Ctr

🇺🇸

Chicago, Illinois, United States

Johns Hopkins Univ School of Medicine

🇺🇸

Baltimore, Maryland, United States

Wayne State Univ / Harper Hosp

🇺🇸

Detroit, Michigan, United States

Univ of Missouri at Kansas City School of Medicine

🇺🇸

Kansas City, Missouri, United States

Infectious Diseases Association / Research Med Ctr

🇺🇸

Kansas City, Missouri, United States

Scroll for more (8 remaining)
Dr Eskild A Petersen
🇺🇸Tucson, Arizona, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.